US retail outlets have removed cough and cold remedies for children from their shelves, following the recent announcement by manufacturers. The decision pre-empts a meeting of the Food and Drug Administration to consider expert recommendations on the future availability of over-the-counter products for children under two-years old.
Both the Stop & Shop Supermarket Company and Giant Food issued statements listing 11 formulations of affected products. These were: Concentrated Tylenol Infants' Drops Plus Cold & Cough; Concentrated Tylenol Infants' Drops Plus Cold & Cough Club Tray; PediaCare Infant Dropper Long-Acting Cough; PediaCare Infant Dropper Decongestant (containing pseudoephedrine); PediaCare Infant Dropper Decongestant & Cough; PediaCare Infant Dropper Decongestant & Cough (containing pseudoephedrine); CareOne Infant Cough and Cold Cherry 0.5oz; Triaminic Infant & Toddler Thin Strips Decongestant; Triaminic Infant & Toddler Thin Strips Decongestant Plus Cough; Little Colds Decongestant + Cough 1oz; and Little Colds Multi Symptom Cold 1oz.
Tylenol is marketed by US health care giant Johnson & Johnson while Triaminic is a brand of Switzerland-based drug major Novartis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze